IMTX vs PGEN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IMTX exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health and operational efficiency. While the company maintains an exceptionally strong liquidity position (Current Ratio of 11.72) and low debt, these are overshadowed by a catastrophic 64.90% year-over-year decline in revenue and deeply negative gross margins (-280.87%). The stock currently trades at a speculative premium with a Price/Sales ratio of 28.98 despite shrinking top-line growth. Any potential upside is driven by analyst price targets ($18.75) rather than current financial performance.
PGEN exhibits critical financial instability, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. While the company shows hyper-growth in revenue (283.60% YoY), this is decoupled from profitability, as evidenced by a catastrophic ROE of -571.97% and an operating margin of -474.61%. Valuation metrics are extreme, with a Price/Book ratio of 66.95 and Price/Sales of 144.36, suggesting the stock is trading on pure speculation rather than intrinsic value. The bearish insider sentiment, characterized by a $15.75M sale, further undermines the bullish analyst price targets.
Compare Another Pair
Related Comparisons
IMTX vs PGEN: Head-to-Head Comparison
This page compares Immatics N.V. (IMTX) and Precigen, Inc. (PGEN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.